$9.810
+0.152 (+1.55%)終値時点
- High
- 10.320
- Open
- 9.550
- VWAP
- 9.89
- Vol
- 9.43K
- Mkt Cap
- 89.70M
- Low
- 9.550
- Amount
- 93.28K
- EV/EBITDA, TTM
- 1.54
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
バリュエーション指標
イベントタイムライン
ニュース
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
7.010-16GlobenewswireBragar Eagel & Squire, P.C. Ongoing Inquiry into AlloVir, Inc. for the Benefit of Long-Term Shareholders
7.008-06GlobenewswireALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
7.003-03PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, WMPN, IPG, TURN on Behalf of Shareholders
7.002-26PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, ALVR, WMPN, AVAV on Behalf of Shareholders
ALVR FAQ — answered by Alphio AI
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。